The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 2, 2014, Pages 276-282

  Klabatsa, Astero ^a   Chicklore, Sugama ^b   Barrington, Sally F ^b   Goh, Vicky ^b   Lang Lazdunski, Loic ^a   Cook, Gary J R ^b,c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Mesothelioma; Metabolic tumour volume; Prognosis; Standardised uptakevalue; Total lesion glycolysis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; PEMETREXED; PLATINUM; POVIDONE IODINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CATHETER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PET-CT SCANNER; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; VIDEO ASSISTED THORACOSCOPIC SURGERY; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION STUDY; LUNG TUMOR; MESOTHELIOMA; MORTALITY; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGNOSIS; SCINTISCANNING;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897843266     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2561-1     Document Type: Article

References (27)

1. Brown T, Darnton A, Fortunato L, Rushton L, British Occupational Cancer Burden Study Group. Occupational cancer in Britain. Respiratory cancer sites: larynx, lung and mesothelioma. Br J Cancer 2012;107:S56-70.
2. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685-94.
3. Cao C, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010;5:1692-703.
4. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354:496-507.
5. Scott AM. Current status of positron emission tomography in oncology. Int Med J 2001;31:27-36.
6. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241-5.
7. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;49:S27-32.
8. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 2005;129:1364-70.
9. Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R, et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2000;120:128-33.
10. Sharif S, Zahid I, Routledge T, Scarci M. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12:806-11.
11. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-50S.
12. Uto F, Shiba E, Onoue S, Yoshimura H, Takada M, Tsuji Y, et al. Phantom study on radiotherapy planning using PET/CT-delineation of GTV by evaluating SUV. J Radiat Res 2010;51:157-64.
13. Boucek J, Francis RJ, Green AJ. Automated approach to identification and quantitation of tumour volumes in chemotherapy monitoring using FDG PET. J Nucl Med 2005;46:464P.
14. Lang-Lazdunski L, Bille A, Lal R, Crane P, McLean E, Landau D, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol 2012;7:737-43.
15. Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, et al. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer 2012;48:1244-54.
16. Lee ST, Ghanem M, Herbertson RA, Berlangieri SU, Byrne AJ, Tabone K, et al. Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol 2009;11: 473-9.
17. Genestreti G, Moretti A, Piciucchi S, Tiseo M, Bersanelli M, Scarlattei M, et al. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma. Technol Cancer Res Treat 2012;11:163-7.
18. Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010;16:2409-17.
19. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48:1449-58.
20. Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 2007;11:961-9.
21. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999;2:159-71.
22. Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT. Eur J Radiol 2012;81:e19-25.
23. Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 2010;67: 311-7.
24. Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, et al. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 2010;17:2787-94.
25. Kadota K, Kachala SS, Nitadori J, Suzuki K, Dunphy MP, Sima CS, et al. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology. J Thorac Oncol 2012;7:1192-7.
26. Genestreti G, Moretti A, Piciucchi S, Giovannini N, Galassi R, Scarpi E, et al. FDG PET/CT response evaluation in malignant pleural mesothelioma patients treated with talc pleurodesis and chemotherapy. J Cancer 2012;3:241-5.
27. Pleural mesothelioma. In: Edge SB, Byrd DR, Compton CC, et al., editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 271-7.